This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Gilead Sciences, Inc.
Drug Names(s): aztreonam lysine for inhalation, AI, AZLI, GS-9268
Description: Aztreonam lysine is a monobactam antibiotic that inhibits bacterial cell wall synthesis by inhibiting Penicillin Binding Protein 3 (PBP3). The inhalable form utilizes the eFlow Electronic Nebulizer. eFlow features TouchSpray technology that uses a vibrating mesh to dictate particle size.
Deal Structure: In August 2006, Gilead announced that it completed its acquisition of Corus following an initial investment of $25.0 million in Corus in April 2006, which included Corus's aztreonam lysine for inhalation.
Additional information available to subscribers only: